Tarantula venom may offer muscular dystrophy cure
By ANISaturday, January 2, 2010
LONDON - Scientists at University at Buffalo have discovered a protein in tarantula venom that could offer potential treatment for muscular dystrophy (MD).
The research team led by Dr Fredrick Sachs, professor of physiology and biophysics at the University at Buffalo has identified a peptide, called GsMTx4.
The peptide also has potential as a therapy for several other conditions, such as neuropathic pain and atrial fibrillation, reports First Science.
The researchers have formed a start-up biotech company in Buffalo, called the Rose Pharmaceuticals, and are working to develop the peptide into a potential drug.
During the study, the team tested the effect of GsMTx4 on MD mice extensively and found that the drug increased muscle strength and caused no mortality, morbidity or toxicity.
The therapies for muscular dystrophy are classed as “orphan drugs” by the FDA, allowing a shorter testing period than normal drugs. (ANI)
